Utility of 131 I-HLX58-Der for the Precision Treatment: Evaluation of a Preclinical Radio-Antibody-D...
Utility of 131 I-HLX58-Der for the Precision Treatment: Evaluation of a Preclinical Radio-Antibody-Drug-Conjugate Approach in Mouse Models
About this item
Full title
Author / Creator
Liu, Yi , Wang, Xiao , Zhang, Ni , He, Simin , Zhang, Jianping , Xu, Xiaoping and Song, Shaoli
Publisher
New Zealand
Journal title
Language
English
Formats
Publication information
Publisher
New Zealand
Subjects
More information
Scope and Contents
Contents
None of the antibody-drug conjugates (ADCs) targeting Claudin 18.2 (CLDN18.2) have received approval from regulatory authorities due to their limited clinical benefits. Leveraging the radiosensitizing ability of Deruxtecan (DXd) and the internal radiation therapy of
I for tumors, we aimed to develop the first radio-antibody-drug conjugates (RADC...
Alternative Titles
Full title
Utility of 131 I-HLX58-Der for the Precision Treatment: Evaluation of a Preclinical Radio-Antibody-Drug-Conjugate Approach in Mouse Models
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmed_primary_39839455
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmed_primary_39839455
Other Identifiers
E-ISSN
1178-2013
DOI
10.2147/IJN.S501689
